Senti Biosciences (NASDAQ:SNTI) Upgraded to “Hold” at Wall Street Zen

Senti Biosciences (NASDAQ:SNTI) was upgraded by Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently issued reports on SNTI. Chardan Capital upped their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Senti Biosciences Price Performance

NASDAQ:SNTI opened at $0.79 on Friday. The business has a 50 day moving average of $0.95 and a 200 day moving average of $1.38. The company has a market capitalization of $20.77 million, a price-to-earnings ratio of -0.24 and a beta of 2.12. Senti Biosciences has a 1-year low of $0.79 and a 1-year high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last issued its earnings results on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $1.00 million. As a group, sell-side analysts anticipate that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Trading of Senti Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of SNTI. Jane Street Group LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter valued at approximately $40,000. Virtu Financial LLC bought a new position in shares of Senti Biosciences in the fourth quarter worth approximately $46,000. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences in the third quarter worth $117,000. Geode Capital Management LLC increased its stake in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the period. Finally, Armistice Capital LLC bought a new stake in Senti Biosciences during the 2nd quarter valued at $1,883,000. Institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.